FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa ...Middle East

SILVER SPRING, Md., May 19, 2023 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB)...

Hence then, the article about fda approves first topical gene therapy for treatment of wounds in patients with dystrophic epidermolysis bullosa was published today ( Friday 19/05/2023 - 09:04 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa )

Also on site :

• Ground stop issued at O'Hare amid snowfall and icy conditions
• What Is Situs Inversus? Inside Catherine O'Hara's Rare Genetic Condition
• Catherine O'Hara Revealed Struggle With Social Anxiety Years Before Her Death